Blog: MS news

Good news! NICE approves Ocrevus (ocrelizumab) for primary progressive MS

10 May 2019

Source MS Trust: The MS Trust is delighted that Ocrevus (ocrelizumab) has been approved by NICE for NHS treatment of early, inflammatory primary progressive MS.

We both now have hope - MS sisters

9 May 2019

Source BBC: Sisters Zoe Bowman and Vikki Langford were both diagnosed with multiple sclerosis within weeks of each other.

"MS doesn't stop me, it just makes me do things a little differently"

2 May 2019

Source MS Trust: When Emma was diagnosed with MS aged 27, she admits it was a 'devastating' time. But, 10 years later, she is determined to focus on the positives. In this blog, Emma writes about her MS diagnosis, life as a farmer, and why she won't let MS beat her.

Gabapentin and pregabalin - new rules for prescriptions

10 April 2019

Source MS Trust: From 1 April 2019, gabapentin and pregabalin have been reclassified as controlled drugs, leading to changes in how they are prescribed.

Gabapentin and pregabalin are drugs used to treat a range of symptoms caused by MS, such as nerve pain, spasticity and spasms.

Following concerns about misuse of these drugs, on 1 April the law changed so that it is now illegal to possess gabapentin or pregabalin without a prescription and to supply or to sell them to others...

Mitochondria and progressive MS

10 April 2019

Source MS Society: Small but mighty, mitochondria provide the energy that busy nerve cells need to survive.

We spoke with mitochondria expert Dr Don Mahad, from the University of Edinburgh, about what makes them so special - and what goes wrong in MS.

Mitochondria and progressive MS

‘I’m interested in energy production and demand in the brain and spinal cord, and especially how this changes in progressive MS.’ It’s the mitochondria that generate the bulk of this...

Motability offers manual wheelchair lease to customers

10 April 2019

Source Independent Living: An interesting new supplementary service has just been launched by Motability.

T20K in Good Position to Become Preventive MS Treatment, Cyxone Says

10 April 2019

Source Multiple Sclerosis News Today: T20K, Cyxone‘s lead compound for treating multiple sclerosis (MS), seems able to prevent or slow disease progression, according to data from preclinical studies. Based on these findings, the company is confident that T20K might become a prophylactic (preventive) medication for MS in the near future.

New £1.8m research to explore cognitive screening and rehabilitation in multiple sclerosis

10 April 2019

Source University of Nottingham: A new £1.85 million research study led by Professor Roshan das Nair at the Institute of Mental Health aims to develop a new computerised screening tool to detect the “invisible” cognitive impairments that can appear early in the life of a person living with multiple sclerosis (MS).

Anyone taking Plegridy?

10 April 2019

Source MS Trust: NICE will be assessing Plegridy to decide whether it should continue to be prescribed by the NHS in England. We’ll be telling NICE why we think it should be an option. If you are taking Plegridy we’d really like to know what you think of it, your experiences good and bad.

Watch a short film about one of our members, Louise Carr

25 March 2019

One of our members, Louise Carr, had a short film made about her, she was happy to share this with you.